

PRESS RELEASE
19 March 2021 14:00:00 CET



One more university hospital in Denmark is starting up with CoreTherm® treatments.

ProstaLund has today reached an agreement with Sjællands Universitetshospital (SUH) which means the start of CoreTherm treatments shortly.

Sjællands Universitetshospital will be the fifth Danish hospital, and at the same time the third Danish university hospital, to offer CoreTherm® treatments for its patients with benign prostate enlargement. The experiences from other Danish hospitals together with our work in Denmark give continued results. One of our stated goals is that CoreTherm should be offered in all Danish regions and with this agreement we will be one step closer to this goal.

"The fact that SUH is now starting up with thermotherapy treatment is another proof that CoreTherm® is beginning to be well established also in Denmark and has an important place to fill in BPH care," says acting CEO Johan Wennerholm in a comment.

The agreement means that the CoreTherm system will be delivered and installed at Næstved Hospital during March 2021.

For further information, please contact:

Johan Wennerholm, Acting CEO
Tel. +46 (0) 730 429997
Email: johan.wennerholm@prostalund.com

About ProstaLund

ProstaLund AB is a Swedish medical technology company and a leading developer and manufacturer of innovative urological devices and treatments. The company's lead product, CoreTherm, is a patented Thermotherapy treatment method for Benign Prostatic Hyperplasia (BPH) which can be tailored to suit the needs of each individual patient. CoreTherm is used today in hospitals and clinics in Sweden and worldwide. ProstaLund is listed on the Nasdaq First North Growth Market.

Certified Adviser:

Västra Hamnen Corporate Finance AB
Phone: +46 40 200 250
E-mail: ca@vhcorp.se



PRESS RELEASE
19 March 2021 14:00:00 CET

Attachments

One more university hospital in Denmark is starting up with CoreTherm® treatments.